S'abonner

Greater efficacy of SPF 100+ sunscreen compared with SPF 50+ in sunburn prevention during 5 consecutive days of sunlight exposure: A randomized, double-blind clinical trial - 13/03/20

Doi : 10.1016/j.jaad.2019.09.018 
Indermeet Kohli, PhD a, , Cynthia L. Nicholson, MD a, b, , Joshua D. Williams, PhD c, Alexis B. Lyons, MD a, InSeok Seo, PhD c, Prithwiraj Maitra, PhD c, Xiaoyan Tian, MS c, Evren Atillasoy, MD c, Henry W. Lim, MD a, Iltefat H. Hamzavi, MD a,
a Department of Dermatology, Henry Ford Hospital, Detroit, Michigan 
b Department of Dermatology, Wayne State University, Detroit, Michigan 
c Johnson & Johnson Consumer Inc, Skillman, New Jersey 

Reprint requests: Iltefat H. Hamzavi, MD, Department of Dermatology, New Center One, 3031 W Grand Blvd, Ste 800, Detroit, MI 48202.Department of DermatologyNew Center One3031 W Grand Blvd, Ste 800DetroitMI48202

Abstract

Background

Beach vacations are high-risk settings for overexposure to ultraviolet radiation.

Objective

To compare the sunburn protective efficacy of SPF 50+ and SPF 100+ sunscreens under actual use at the beach.

Methods

A prospective, randomized, double-blind, single-center, split-body/face study of 55 healthy individuals. Each participant applied both sunscreens to randomized sides of the face/body for up to 5 consecutive days. Blinded clinical evaluation of erythema by a single grader and objective instrumental assessments, colorimetry, and diffuse reflectance spectroscopy were performed the morning after each sun exposure.

Results

After 5 days, 31 (56%) participants had more sunburn on the SPF 50+ side compared to 4 (7%) on the SPF 100+ side. Overall, mean erythema intensity showed statistically significantly less erythema on the SPF 100+ side compared with the SPF 50+ side. The first observation of sunburn exclusively on the SPF 50+ side occurred after 1 day of sun exposure, whereas that for SPF 100+ occurred after 3 days of sun exposure.

Limitations

Only initial sunscreen application was monitored, only 1 participant with skin phototype I was recruited, and participants were recruited from a local beach area.

Conclusion

SPF 100+ was significantly more effective in protecting against ultraviolet radiation–induced erythema and sunburn than SPF 50+ in actual use in a beach vacation setting.

Le texte complet de cet article est disponible en PDF.

Key words : beach, clinical research, general dermatology, medical dermatology, prevention, SPF, sun protection factor, sunlight, sunscreen, vacation

Abbreviations used : a*, CI, DRS, HbO2, SPF, SPT, UPF, UV


Plan


 Supported by Johnson & Johnson Consumer Inc. The funding source was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
 Disclosure: This protocol was designed by the Henry Ford Hospital Department of Dermatology with a fee for protocol development paid to the institution by Johnson & Johnson. Dr Kohli is an investigator for Ferndale, Estee Lauder, Unigen, Johnson & Johnson, Allergan, and Bayer and is a consultant for Pfizer, Johnson & Johnson, and Bayer. Dr Lyons is a subinvestigator for Estee Lauder, Unigen, and Bayer. Dr Lim is an investigator for Estee Lauder, Ferndale, Unigen, and Incyte; is a consultant for Pierre Fabre and ISDIN; and has served as a speaker in an educational session sponsored by Pierre Fabre and Eli Lilly. Dr Hamzavi is an investigator for Estee Lauder, Ferndale, Unigen, Johnson & Johnson, Bayer, Allergan, and Incyte and is a consultant for Pfizer, Johnson & Johnson, and Bayer. Drs Williams, Seo, Maitra, and Atillasoy and Mr Tian are fulltime employees of Johnson & Johnson Consumer Inc. Dr Nicholson has no conflicts of interest to declare.
 Partial results of this study were presented in poster format at the American Academy of Dermatology Annual Meeting, Orlando, FL, March 2017, and at the American Academy of Dermatology Annual Meeting in San Diego, CA, March 2018.
 IRB approval status: Reviewed and approved by IRB Services (Aurora, Ontario, Canada).


© 2020  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 82 - N° 4

P. 869-877 - avril 2020 Retour au numéro
Article précédent Article précédent
  • A regimen to minimize pain during blue light photodynamic therapy of actinic keratoses: Bilaterally controlled, randomized trial of simultaneous versus conventional illumination
  • Urvashi Kaw, Muneeb Ilyas, Taylor Bullock, Lisa Rittwage, Margo Riha, Allison Vidimos, Bo Hu, Christine B. Warren, Edward V. Maytin
| Article suivant Article suivant
  • Restaging [18F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance
  • Sonia Mahajan, Christopher A. Barker, Audrey Mauguen, Bhuvanesh Singh, Neeta Pandit-Taskar

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.